

Curriculum Vitae

Personal information

Laetitia Croux Belgodere

Work experience

1. Employer: AP_HP
 - Start date: 112010
 - End date: 042015
 - Position: Pharmacy resident
 - Activities: Residency in hospital pharmacies (AP_HP: Necker, Louis Mourier, Avicenne, Hotel Dieu), oncology clinical service (AP_HP: Tenon)
 - Country: France
2. Employer: ANSM
 - Start date: 092015
 - End date:
 - Position: Clinical efficacy and safety assessor, then scientific project manager
 - Activities: Clinical assessor in oncology and onco_haematology; then support for the General Management on scientific strategy, coordination of scientific projects
 - Country: France

Education and training

1. Subject: Paris Sud University (pharmacy faculty)
 - Start date: 092005
 - End date: 042015
 - Qualification: Pharm D.
 - Organisation: General studies of pharmacy (2005_2010), Internship in pharmacy (2010_2015), Specialised diploma in pharmaceutical sciences
 - Country: France
2. Subject: Paris Sud University (medicine faculty), ENS Cachan
 - Start date: 092011
 - End date: 062012
 - Qualification: Master degree
 - Organisation: Oncology; Specialization in "Pharmacology and Therapeutics"
 - Country: France
3. Subject: University Pierre and Marie Curie Paris VI
 - Start date: 092012
 - End date: 062013
 - Qualification: University diploma
 - Organisation: Teaching Centre for Statistics in Public Health, Medicine and Biology/ Biostatistics and interpretation of clinical trials (CESA)
 - Country: France
4. Bordeaux school of public health (ISPED)
 - Start date: 102018
 - End date: 072019
 - Qualification: University diploma
 - Organisation: Methods and practice in medico_economic evaluation
 - Country: France

Additional information

Publications

Belgodère L, Bertrand DP, Jaulent MC, *et al.* Patient and public involvement in the benefit–risk assessment and risk management of medicinal products. *Drug Information Journal*. 2017;51(1):1-12.

Belgodère L, Emmerich J, Albin N, *et al.* Prevention and management of health products shortages by the French Republic. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(1):1-12.

Boichard A, Croux L, Al Ghuzlan A, *et al.* Somatic RAS mutations occur in a large proportion of sporadic RET-activating rearrangements. *Journal of Clinical Investigation*. 2017;127(1):1-12.

Christen C, Belgodère L, Guillot B, *et al.* Access to innovation through the national early access program and the French Republic. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(1):1-12.

Jacquet E, Kerouani-Lafaye G, Grude F, *et al.* Comparative study on anticancer drug access times between France and the United Kingdom. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(1):1-12.

Lapière J, Christen C, Kerouani-Lafaye G, *et al.* Evaluation of Clinical Trials in Onco-haematology: A New Methodology. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(1):1-12.

Maison P, Bacon T, Daynes P, *et al.* Concilier régulation du médicament et démocratie sanitaire : rôle des comités de suivi des médicaments. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(1):1-12.

Oualikene-Gonin W, Jaulent M-C, Thierry J-P, *et al.* Artificial intelligence integration in the drug lifecycle and in

Oualikene-Gonin W, Sautou V, Ezan E, *et al.* Regulatory assessment of nano-enabled health products in publ

[Projects](#)

[Memberships](#)

[Other](#)

[Relevant](#)

[Information](#)